Ivory

Ivory is a biotechnology company focused on developing a new class of medicines designed to target the root causes of autoimmune and inflammatory diseases. By leveraging a precision immunology platform, the company aims to identify specific immune system drivers that lead to chronic disease states. Ivory's approach combines deep biological insights with advanced drug discovery technologies to create highly targeted therapies. The company is currently in the pre-clinical stage, building a pipeline of candidates intended to provide more effective and durable treatments for patients with limited options. Ivory is headquartered in San Francisco and is backed by prominent life science investors.